Материалов:
1 005 012

Репозиториев:
30

Авторов:
761 409

По вашему запросу найдено документов: 4020

Страница 1 из 402

The application of porphyrins and their analogues for inactivation of viruses
Lebedeva N.Sh.
inactivation of human and animal viruses using porphyrins and their analogues and to analyze and discuss
Use of live attenuated influenza vaccines in young children in resource-poor settings
Isakova-Sivak I.
inactivated vaccine
The Application of Porphyrins and Their Analogues for Inactivation of Viruses
Sh Lebedeva
inactivation of human and animal viruses using porphyrins and their analogues and to analyze and discuss
Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories
Rudenko L.
vaccines (GAP). WHO, recognizing potential advantages of LAIV over the inactivated influenza vaccine in a
Inactivation of airborne influenza virus in the ambient air
Pyankov Oleg V.
Resent respiratory infection outbreak events, including Avian and Swine Influenza and SARS virus
The potential of influenza HA-specific immunity in mitigating lethality of postinfluenza pneumococcal infections
Klausberger M.
hemagglutinin Gag virus like particles that had been differentially treated for the inactivation of bioprocess
Viral genome cleavage with artificial ribonucleases: A new method to inactivate RNA-containing viruses
Goncharova E. P.
Viral genome cleavage with artificial ribonucleases: A new method to inactivate RNA
An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/ 05) influenza vaccine is safe and immunogenic in a single dose in humans
Sansyzbay A.R.
of hemagglutinin [HA]) of a whole-virion inactivated prepandemic influenza vaccine adjuvanted with aluminum
Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine
Rudenko L.
) inactivated influenza vaccine (IIV) in healthy adult subjects who received A(H5N2) live attenuated influenza
Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults
Sarsenbayeva G.
vaccine contained 15 μg of hemagglutinin of each influenza virus strain recommended by WHO

Страница 1 из 402

Фасеты

Новости проекта

Новости

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core